A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer.

Baba K, Suzuki N, Imamura CK, Booka E, Takeuchi M, Takahari D, Kawakami T, Kawakubo H, Kitagawa C, Kono Y, Ogura K, Kito Y, Saito K, Yamamoto S, Takeuchi H, Kudo T, Tsunoda T, Mizukami T, Yamaguchi T, Shoji H, Saito K, Tanoue K, Baba E, Nagashima K, Boku N

Open source

DOI: 10.1186/s12885-025-14084-1
Published: 2025 Apr 12
Container: BMC cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-025-14084-1,
  title = {A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer.},
  author = {Baba K and Suzuki N and Imamura CK and Booka E and Takeuchi M and Takahari D and Kawakami T and Kawakubo H and Kitagawa C and Kono Y and Ogura K and Kito Y and Saito K and Yamamoto S and Takeuchi H and Kudo T and Tsunoda T and Mizukami T and Yamaguchi T and Shoji H and Saito K and Tanoue K and Baba E and Nagashima K and Boku N},
  year = {2025},
  journal = {BMC cancer},
  doi = {10.1186/s12885-025-14084-1},
  url = {https://doi.org/10.1186/s12885-025-14084-1}
}

RIS

TY  - JOUR
TI  - A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer.
AU  - Baba K
AU  - Suzuki N
AU  - Imamura CK
AU  - Booka E
AU  - Takeuchi M
AU  - Takahari D
AU  - Kawakami T
AU  - Kawakubo H
AU  - Kitagawa C
AU  - Kono Y
AU  - Ogura K
AU  - Kito Y
AU  - Saito K
AU  - Yamamoto S
AU  - Takeuchi H
AU  - Kudo T
AU  - Tsunoda T
AU  - Mizukami T
AU  - Yamaguchi T
AU  - Shoji H
AU  - Saito K
AU  - Tanoue K
AU  - Baba E
AU  - Nagashima K
AU  - Boku N
PY  - 2025
JO  - BMC cancer
DO  - 10.1186/s12885-025-14084-1
UR  - https://doi.org/10.1186/s12885-025-14084-1
ER  -

APA

K, B., N, S., CK, I., E, B., M, T., D, T., T, K., H, K., C, K., Y, K., K, O., Y, K., K, S., S, Y., H, T., T, K., T, T., T, M., T, Y., H, S., K, S., K, T., E, B., K, N., & N, B. (2025). A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer.. BMC cancer. https://doi.org/10.1186/s12885-025-14084-1

Source records

pubmed · retrieved 2026-09-26T08:22:11.532Z